| Autor: |
Shu B, Kirby MK, Davis WG, Warnes C, Liddell J, Liu J, Wu KH, Hassell N, Benitez AJ, Wilson MM, Keller MW, Rambo-Martin BL, Camara Y, Winter J, Kondor RJ, Zhou B, Spies S, Rose LE, Winchell JM, Limbago BM, Wentworth DE, Barnes JR |
| Jazyk: |
angličtina |
| Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2021; Vol. 27 (7), pp. 1821-1830. |
| DOI: |
10.3201/eid2707.210462 |
| Abstrakt: |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 10 2.0 , influenza B virus at 10 2.2 , and SARS-CoV-2 at 10 0.3 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
